Europe Heart Valve Repair and Replacement Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Heart Valve Repair and Replacement Market Size

• The Europe heart valve repair and replacement market size was valued at USD 1.50 billion in 2025 and is expected to reach USD 3.71 billion by 2033, at a CAGR of 12.0% during the forecast period
• The market growth is largely driven by the rising prevalence of valvular heart diseases, an aging population, and continuous advancements in minimally invasive and transcatheter heart valve technologies across the region
• Furthermore, increasing preference for less invasive procedures, improved clinical outcomes, and growing adoption of advanced bioprosthetic and mechanical valves are establishing heart valve repair and replacement as critical interventions in cardiovascular care. These converging factors are accelerating procedural volumes and technological uptake, thereby significantly boosting the market’s growth

Europe Heart Valve Repair and Replacement Market Analysis

• Heart valve repair and replacement solutions, including surgical and transcatheter products for treating structural heart diseases, are increasingly vital components of advanced cardiovascular care across Europe due to their proven clinical effectiveness, improved patient outcomes, and expanding use in both elective and emergency cardiac interventions
• The escalating demand for heart valve repair and replacement is primarily fueled by the rising prevalence of valvular stenosis and insufficiency, a rapidly aging population, and growing adoption of minimally invasive and non-surgical procedures such as TAVI/TAVR
• Germany dominated the Europe heart valve repair and replacement market with a revenue share of 29.6% in 2025, supported by high procedure volumes, strong reimbursement frameworks, advanced hospital infrastructure, and early adoption of transcatheter valve technologies across major cardiac centers
• France is expected to be the fastest growing country during the forecast period driven by increasing investments in interventional cardiology, expanding access to non-surgical procedures, and favorable healthcare policies
• TAVI / TAVR valves segment dominated the market with a share of 41.3% in 2025, driven by strong clinical adoption for valvular stenosis cases, particularly among elderly and high-risk patients, and the continued shift away from conventional open-heart surgical procedures

Report Scope and Europe Heart Valve Repair and Replacement Market Segmentation       

Europe Heart Valve Repair and Replacement Market Trends

Rising Adoption of Minimally Invasive and Transcatheter Procedures

• A significant and accelerating trend in the Europe heart valve repair and replacement market is the growing shift toward minimally invasive and transcatheter procedures, particularly TAVI/TAVR, driven by improved clinical outcomes and reduced procedural risks compared to conventional open-heart surgery
  • For instance, transcatheter aortic valve implantation has become a preferred treatment option across major European countries such as Germany and France, especially for elderly and high-risk patients who are not ideal candidates for surgical procedures
• Technological advancements in valve design, imaging guidance, and catheter-based delivery systems are enabling greater procedural precision, shorter hospital stays, and faster patient recovery. For instance, newer-generation TAVI valves offer enhanced durability and lower rates of paravalvular leakage
• The integration of advanced imaging modalities and digital planning tools is facilitating better pre-procedural assessment and post-procedural monitoring, allowing clinicians to optimize treatment strategies for individual patients
• This trend toward less invasive, more patient-centric treatment approaches is reshaping clinical practice patterns and treatment guidelines across Europe, encouraging broader adoption of heart valve repair and replacement therapies
• Consequently, leading medical device manufacturers are increasingly focusing on expanding their transcatheter valve portfolios and clinical trial programs to address a wider patient population and strengthen their presence in the European market
• In addition, rising collaborations between hospitals, research institutes, and device manufacturers are fostering innovation and accelerating the introduction of next-generation heart valve technologies

Europe Heart Valve Repair and Replacement Market Dynamics

Driver

Growing Disease Burden and Aging Population Across Europe

• The increasing prevalence of valvular heart diseases, combined with Europe’s rapidly aging population, is a major driver for the rising demand for heart valve repair and replacement procedures
  • For instance, degenerative aortic stenosis is increasingly diagnosed among elderly populations in countries such as Germany, Italy, and Spain, significantly boosting the need for valve replacement interventions
• Advancements in diagnostic technologies and improved access to cardiac screening programs are enabling earlier detection of valvular disorders, thereby increasing treatment rates
• Furthermore, favorable reimbursement policies and strong healthcare infrastructure in several European countries are supporting higher adoption of both surgical and non-surgical heart valve procedures
• The growing awareness among patients and clinicians regarding the benefits of timely valve intervention, including improved survival and quality of life, continues to propel market growth
• Increasing investments by governments and healthcare providers in cardiovascular care infrastructure are further supporting higher procedural volumes across Europe
• In addition, expanding indications for heart valve repair and replacement therapies are enabling treatment of a broader patient population, contributing to sustained market expansion

Restraint/Challenge

High Procedure Costs and Stringent Regulatory Requirements

• The high cost associated with advanced heart valve repair and replacement procedures, particularly TAVI/TAVR, poses a significant challenge to broader market penetration across Europe
  • For instance, transcatheter valve procedures involve expensive devices, specialized infrastructure, and highly trained clinical teams, which can limit accessibility in cost-sensitive healthcare systems
• Stringent regulatory approval processes and rigorous clinical evidence requirements in Europe can delay product launches and increase development costs for manufacturers
• In addition, disparities in reimbursement policies across countries may restrict patient access to advanced valve therapies, particularly in emerging European markets
• Overcoming these challenges through cost optimization, expanded reimbursement coverage, and streamlined regulatory pathways will be essential for ensuring sustained growth of the Europe heart valve repair and replacement market
• Limited availability of specialized cardiac centers in certain regions can further constrain patient access to advanced valve interventions
• Moreover, long-term durability concerns and the need for extended clinical follow-up for newer valve technologies may slow adoption among conservative healthcare providers

Europe Heart Valve Repair and Replacement Market Scope

The market is segmented on the basis of product, procedure, indication, end user, and distribution channel.

• By Product

On the basis of product, the Europe heart valve repair and replacement market is segmented into surgical heart valves replacement, surgical heart valves repair, TAVI / TAVR valves, grafts, patches, medication, and others. The TAVI / TAVR valves segment dominated the market in 2025 with a market share of 41.3%, driven by strong clinical adoption for the treatment of valvular stenosis, particularly aortic stenosis, across Europe. These valves are widely preferred for elderly and high-risk patients due to their minimally invasive nature and lower perioperative mortality rates. Reduced hospital stays and faster post-procedure recovery significantly improve patient outcomes. Strong reimbursement support in countries such as Germany and France has encouraged higher procedure volumes. Continuous innovation in valve materials and delivery systems is improving durability and safety. Expanding clinical indications are further strengthening the dominance of this segment.

The surgical heart valves repair segment is anticipated to witness the fastest growth during the forecast period, fueled by increasing preference for repair over replacement in younger and low-risk patients. Valve repair preserves native valve anatomy and reduces the need for lifelong anticoagulation therapy. Advancements in surgical imaging and repair techniques are improving procedural success rates. Rising diagnosis of mitral valve prolapse is increasing demand for repair procedures. Favorable long-term outcomes compared to replacement are supporting wider clinical adoption. Growing expertise among cardiac surgeons across Europe is accelerating segment growth.

• By Procedure

On the basis of procedure, the Europe heart valve repair and replacement market is segmented into surgical procedure and non-surgical procedure. The non-surgical procedure segment dominated the market in 2025, driven by the rapid expansion of transcatheter valve interventions across Europe. These procedures significantly reduce surgical trauma and recovery time compared to open-heart surgery. High adoption among elderly and co-morbid patients supports segment dominance. Increasing availability of catheterization labs is facilitating wider access. Strong clinical trial data continues to validate safety and efficacy. Favorable reimbursement frameworks further support sustained dominance.

The surgical procedure segment is expected to witness the fastest growth during the forecast period, supported by ongoing demand for complex and multi-valve disease treatment. Certain patient groups still require open surgical intervention for optimal outcomes. Advancements in minimally invasive surgical techniques are reducing operative risks. Improved post-operative care is enhancing recovery rates. Increasing surgical expertise across European cardiac centers supports higher procedure volumes. Rising referrals for complex cases are further contributing to growth.

• By Indication

On the basis of indication, the Europe heart valve repair and replacement market is segmented into valvular stenosis, valvular insufficiency, mitral valve prolapse, and others. The valvular stenosis segment dominated the market in 2025, primarily due to the high prevalence of aortic stenosis among Europe’s aging population. Degenerative valve disease incidence increases significantly with age. TAVI/TAVR procedures are primarily indicated for stenosis management. Improved screening programs are enabling earlier diagnosis. Strong clinical outcomes have established valve replacement as the standard of care. High procedural volumes continue to sustain segment dominance.

The valvular insufficiency segment is expected to grow at the fastest rate during the forecast period, driven by increasing diagnosis of mitral and tricuspid regurgitation. Growing awareness among clinicians is leading to earlier intervention. Rising preference for valve repair procedures supports expansion. Technological advancements in repair devices are improving treatment success. Expanding use of minimally invasive repair techniques is increasing adoption. Broadening treatment eligibility criteria is further accelerating growth.

• By End User

On the basis of end user, the Europe heart valve repair and replacement market is segmented into hospital, specialty centers, cardiac catheterization lab, ambulatory surgical centers, and others. The hospital segment dominated the market in 2025 due to the presence of advanced cardiac infrastructure and specialized medical staff. Most complex valve procedures are performed in hospital settings. Availability of hybrid operating rooms enhances procedural efficiency. High patient inflow supports large procedure volumes. Favorable reimbursement structures encourage hospital-based interventions. Strong emergency care capabilities further reinforce dominance.

The cardiac catheterization lab segment is projected to witness the fastest growth during the forecast period, driven by the rising number of transcatheter valve procedures. Increasing investment in catheter-based infrastructure supports expansion. Shorter procedure times improve patient throughput. Growing decentralization of cardiac care is boosting utilization. Rising physician preference for minimally invasive settings is accelerating growth. Improved access in urban and semi-urban regions further supports adoption.

• By Distribution Channel

On the basis of distribution channel, the Europe heart valve repair and replacement market is segmented into direct tender, retail sales, and others. The direct tender segment dominated the market in 2025, driven by centralized procurement practices across European healthcare systems. Public hospitals rely heavily on tender-based purchasing. Bulk procurement enables cost efficiency for high-value devices. Long-term supplier contracts ensure consistent availability. Strong regulatory oversight supports standardized purchasing. High-volume demand sustains dominance of this channel.

The retail sales segment is expected to witness the fastest growth during the forecast period, fueled by the expansion of private hospitals and specialty cardiac centers. Increasing elective and outpatient procedures are driving demand. Faster procurement cycles improve operational flexibility. Growing private healthcare expenditure helps in supports expansion. Improved distributor networks enhance accessibility. The rising preference for customized purchasing is further accelerating growth.

Europe Heart Valve Repair and Replacement Market Regional Analysis

• Germany dominated the Europe heart valve repair and replacement market with a revenue share of 29.6% in 2025, supported by high procedure volumes, strong reimbursement frameworks, advanced hospital infrastructure, and early adoption of transcatheter valve technologies across major cardiac centers
• Healthcare providers in Germany place high emphasis on early diagnosis and timely intervention, supported by a dense network of specialized cardiac centers, experienced clinicians, and widespread adoption of advanced technologies such as TAVI/TAVR
• This dominance is further reinforced by favorable reimbursement frameworks, strong public healthcare funding, and continuous investments in cardiac infrastructure, establishing Germany as the leading country for heart valve repair and replacement procedures in Europe

The Germany Heart Valve Repair and Replacement Market Insight

Germany dominated the Europe heart valve repair and replacement market in 2025, supported by high procedure volumes and advanced healthcare infrastructure. The country has a dense network of specialized cardiac centers and strong adoption of transcatheter valve technologies. German clinicians are early adopters of innovative treatment approaches, particularly for aortic stenosis. Comprehensive reimbursement coverage enables broad patient access to advanced procedures. Continuous clinical research and innovation further strengthen Germany’s leadership. As a result, Germany remains the key revenue contributor within Europe.

France Heart Valve Repair and Replacement Market Insight

The France heart valve repair and replacement market is projected to expand at a steady CAGR during the forecast period, driven by strong government support for cardiovascular care. Increasing adoption of minimally invasive procedures is improving patient outcomes. France has well-established cardiac centers with growing expertise in TAVI/TAVR interventions. Rising awareness of valvular diseases is supporting early diagnosis. Favorable reimbursement policies further encourage treatment uptake. These factors collectively support sustained market growth in France.

U.K. Heart Valve Repair and Replacement Market Insight

The U.K. heart valve repair and replacement market is expected to grow at a notable CAGR during the forecast period, driven by increasing demand for advanced cardiac interventions. The National Health Service plays a key role in expanding access to valve procedures. Growing adoption of minimally invasive techniques is reducing surgical burden. Rising incidence of valvular disorders among the elderly is boosting demand. Investments in cardiac catheterization labs are supporting procedural growth. Continued focus on improving cardiovascular outcomes is sustaining market expansion.

Italy Heart Valve Repair and Replacement Market Insight

The Italy heart valve repair and replacement market is experiencing steady growth due to an aging population and rising prevalence of degenerative valve diseases. Increasing adoption of TAVI/TAVR procedures is supporting market development. Italian cardiac centers are expanding minimally invasive treatment capabilities. Improved diagnostic practices are leading to higher treatment rates. Public healthcare coverage supports access to advanced therapies. These factors are contributing to gradual market expansion in Italy.

Europe Heart Valve Repair and Replacement Market Share

The Europe Heart Valve Repair and Replacement industry is primarily led by well-established companies, including:

• Edwards Lifesciences Corporation (U.S.)
• Medtronic (Ireland)
• Boston Scientific Corporation (U.S.)
• Abbott (U.S.)
• LivaNova PLC (U.K.)
• Corcym Group (Italy)
• JenaValve Technology, Inc. (U.S.)
• Xeltis (Switzerland)
• CryoLife, Inc. (U.S.)
• Braile Biomedica (Brazil)
• Neovasc Inc. (Canada)
• Artivion, Inc. (U.S.)
• Valtech Cardio (Israel)
• Micro Interventional Devices (U.S.)
• MitrAssist (U.S.)
• Colibri Heart Valve, Inc. (U.S.)
• Lepu Medical Technology Co., Ltd. (China)
• Valve Medical ApS (Denmark)
• 4Tech Cardio S.p.A. (Italy)

What are the Recent Developments in Europe Heart Valve Repair and Replacement Market?

• In September 2025, European Society of Cardiology (ESC) and EACTS guidelines formally recognized TAVI as a Class IIb recommended option for treating severe symptomatic aortic regurgitation in patients ineligible for surgery the first time TAVI is officially recommended for this indication in Europe
• In August 2025, Abbott’s Navitor™ TAVI system received expanded CE Mark approval in Europe to treat aortic stenosis in low and intermediate surgical-risk patients, significantly broadening the eligible patient base beyond high-risk categories
• In April 2025, Edwards Lifesciences’ SAPIEN M3 transfemoral transcatheter mitral valve replacement system received CE Mark in Europe, becoming the world’s first approved transcatheter mitral valve replacement using a transfemoral approach for patients with symptomatic mitral regurgitation who are unsuitable for surgery or edge-to-edge repair
• In January 2025, Medtronic received CE Mark for its Harmony™ Transcatheter Pulmonary Valve (TPV) System in the EU offering a minimally invasive alternative for patients with pulmonary valve regurgitation and expanding transcatheter valve therapy beyond aortic and mitral positions
• In September 2024, TRiCares announced the first implantation of its Topaz transcatheter tricuspid valve replacement (TTVR) system in the EU pivotal study, marking a significant step toward new transcatheter tricuspid valve therapy for patients with tricuspid regurgitation who are not candidates for open surgery

SKU-63636